Difference between revisions of "Heparin-induced thrombocytopenia"
Jump to navigation
Jump to search
Tag: visualeditor |
m |
||
| Line 18: | Line 18: | ||
=All lines of therapy= | =All lines of therapy= | ||
==Argatroban monotherapy== | ==Argatroban monotherapy== | ||
| + | ===Regimen=== | ||
{| class="wikitable" | {| class="wikitable" | ||
!Study | !Study | ||
| Line 24: | Line 25: | ||
!Efficacy | !Efficacy | ||
|- | |- | ||
| − | |[https://www. | + | |[https://www.ahajournals.org/doi/abs/10.1161/circ.103.14.1838 Lewis et al. 2001 (ARG-911)] |
|Prospective, historical control | |Prospective, historical control | ||
|Multiple | |Multiple | ||
|Reduced all-cause death, all-cause amputation, and new thrombosis | |Reduced all-cause death, all-cause amputation, and new thrombosis | ||
|} | |} | ||
| + | ====Anticoagulation==== | ||
| + | *[[Argatroban (Acova)]] 2 mcg/kg/min IV adjusted to maintain activated partial thromboplastin time 1.5 to 3.0 times baseline value. | ||
| − | === | + | ===References=== |
| − | + | # '''ARG-911:''' Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, Bartholomew J, Sham R, Lerner RG, Zeigler ZR, Rustagi PK, Jang IK, Rifkin SD, Moran J, Hursting MJ, Kelton JG; ARG-911 Study Investigators. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001 Apr 10;103(14):1838-43. [https://www.ahajournals.org/doi/abs/10.1161/circ.103.14.1838 link to original article.] [https://www.ncbi.nlm.nih.gov/pubmed/11294800 PubMed.] | |
| − | |||
| − | |||
| − | |||
[[Category:Heparin-induced thrombocytopenia (HIT) regimens]] | [[Category:Heparin-induced thrombocytopenia (HIT) regimens]] | ||
Revision as of 18:19, 9 September 2018
| Section editors | |||
|---|---|---|---|
 |
Shruti Chaturvedi, MBBS, MSCI Baltimore, MD |
 |
Benjamin Tillman, MD Nashville, TN |
0 regimens on this page
0 variants on this page
|
Guidelines
To be completed
All lines of therapy
Argatroban monotherapy
Regimen
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Lewis et al. 2001 (ARG-911) | Prospective, historical control | Multiple | Reduced all-cause death, all-cause amputation, and new thrombosis |
Anticoagulation
- Argatroban (Acova) 2 mcg/kg/min IV adjusted to maintain activated partial thromboplastin time 1.5 to 3.0 times baseline value.
References
- ARG-911: Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, Bartholomew J, Sham R, Lerner RG, Zeigler ZR, Rustagi PK, Jang IK, Rifkin SD, Moran J, Hursting MJ, Kelton JG; ARG-911 Study Investigators. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001 Apr 10;103(14):1838-43. link to original article. PubMed.